Aptose Biosciences Inc.’s License Agreement with Hanmi Pharmaceutical

Aptose Biosciences Inc.'s License Agreement with Hanmi Pharmaceutical

McCarthy Tétrault advised Aptose Biosciences on the deal.

Aptose Biosciences Inc. has entered into an exclusive license agreement with Hanmi Pharmaceutical to develop and commercialize HM43239.

Under the terms of the agreement, Aptose has been granted exclusive rights to develop and commercialize HM43239, and Hanmi will receive an upfront payment of US$12.5 million as well as up to US$407.5 million in future milestone payments contingent upon the achievement of certain clinical, regulatory and sales milestones across several potential indications, as well as tiered royalties on net sales. HM43239 is an oral, clinical-stage myeloid kinome inhibitor (MKI) designed to target kinases operative in myeloid malignancies, and has shown promising responses in patients with relapsed or refractory acute myeloid leukemia.

Aptose Biosciences (NASDAQ:APTO), headquartered in Toronto, Ontario, is a clinical-stage biotechnology company. It focuses on the discovery, research and development of anti-cancer therapies.

Founded in 1973, Hanmi Pharmaceutical is a South Korean pharmaceutical company. 

The McCarthy Tétrault team included Charles-Antoine Soulière (Picture) and Farhiyah Shariff.

Involved fees earner: Farhiyah Shariff – McCarthy Tétrault; Charles-Antoine Soulière – McCarthy Tétrault;

Law Firms: McCarthy Tétrault;

Clients: Aptose Biosciences Inc.;

Sonia Carcano

Author: Sonia Carcano